Literature DB >> 15208491

The use of standardized uptake values for assessing FDG uptake with PET in oncology: a clinical perspective.

G Lucignani1, G Paganelli, E Bombardieri.   

Abstract

Among clinicians who use positron emission tomography (PET), the standardized uptake value (SUV) is a popular semi-quantitative value that can be easily assessed whenever a PET study is performed under physiological and pathological conditions. It provides an index of regional tracer uptake normalized to the administered dose of tracer. The simplicity of SUV assessment contrasts with the complexity of full quantitative procedures requiring blood sampling and possibly dynamic scanning, which limits patient throughput and significantly increases the workload of a PET centre. Two main clinical conditions/variables affect the significance and usefulness of the SUV: the type and stage of the disease being assessed. Diagnosis, prognosis and therapy monitoring represent the possible uses of SUV. In the above clinical conditions an SUV may provide information about the single lesion in which it is assessed, but the utility of such information depends largely on its integration with all the available clinical and instrumental data.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15208491     DOI: 10.1097/01.mnm.0000134329.30912.49

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  31 in total

1.  Whole-body metabolic tumour volume of 18F-FDG PET/CT improves the prediction of prognosis in small cell lung cancer.

Authors:  Jong-Ryool Oh; Ji-Hyoung Seo; Ari Chong; Jung-Joon Min; Ho-Chun Song; Young-Chul Kim; Hee-Seung Bom
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-01-21       Impact factor: 9.236

2.  Feasibility study of the use of similarity maps in the evaluation of oncological dynamic positron emission tomography images.

Authors:  T Thireou; G Kontaxakis; L G Strauss; A Dimitrakopoulou-Strauss; S Pavlopoulos; A Santos
Journal:  Med Biol Eng Comput       Date:  2005-01       Impact factor: 2.602

3.  SUV and segmentation: pressing challenges in tumour assessment and treatment.

Authors:  Giovanni Lucignani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-04       Impact factor: 9.236

4.  Prognostic value of whole-body metabolic tumour volume and total lesion glycolysis measured on ¹⁸F-FDG PET/CT in patients with extranodal NK/T-cell lymphoma.

Authors:  Choon-Young Kim; Chae Moon Hong; Do-Hoon Kim; Seung Hyun Son; Shin Young Jeong; Sang-Woo Lee; Jaetae Lee; Byeong-Cheol Ahn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-15       Impact factor: 9.236

Review 5.  Quantitative imaging biomarkers in nuclear medicine: from SUV to image mining studies. Highlights from annals of nuclear medicine 2018.

Authors:  Martina Sollini; Francesco Bandera; Margarita Kirienko
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-11-05       Impact factor: 9.236

6.  Duodenal Adenocarcinoma at the Ligament of Treitz: Management and Outcome.

Authors:  Andrew R Biello; Kevin M Lin-Hurtubise; Freeman J Condon; Evan J Allen
Journal:  Hawaii J Health Soc Welf       Date:  2019-10

7.  Quantification of [18F]UCB-H Binding in the Rat Brain: From Kinetic Modelling to Standardised Uptake Value.

Authors:  Maria Elisa Serrano; Mohamed Ali Bahri; Guillaume Becker; Alain Seret; Frédéric Mievis; Fabrice Giacomelli; Christian Lemaire; Eric Salmon; André Luxen; Alain Plenevaux
Journal:  Mol Imaging Biol       Date:  2019-10       Impact factor: 3.488

8.  Nuclear Medicine Imaging Procedures in Oncology.

Authors:  Ajay-Mohan Mohan; Nicola Beindorff; Winfried Brenner
Journal:  Methods Mol Biol       Date:  2021

9.  Quantitative accuracy of PET/CT for image-based kinetic analysis.

Authors:  Youngho Seo; Boon-Keng Teo; Mohiuddin Hadi; Carole Schreck; Stephen L Bacharach; Bruce H Hasegawa
Journal:  Med Phys       Date:  2008-07       Impact factor: 4.071

10.  Diagnostic value of combined ¹⁸F-FDG PET/MRI for staging and restaging in paediatric oncology.

Authors:  Thomas Pfluger; Henriette I Melzer; Wolfgang P Mueller; Eva Coppenrath; Peter Bartenstein; Michael H Albert; Irene Schmid
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-08-28       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.